Alain Fournier

Expertises

Chimie médicinale , Pharmacologie

  • Professeur associé

Centre Armand-Frappier Santé Biotechnologie

531, boulevard des Prairies
Laval (Québec)  H7V 1B7
Canada

Voir le centre

Intérêts de recherche

Les peptides constituent une classe de molécules biologiques possédant diverses fonctions. Ainsi, ils peuvent agir comme hormones, facteurs de croissance, agents de signalisation cellulaire, antibiotiques, neurotransmetteurs, neuromodulateurs, etc. Ce spectre d’activités de même que la spécificité relative des peptides et leur puissance d’action en font des constituants biologiques dont l’élucidation des rôles constitue un objectif majeur dans le domaine biomédical. Ainsi, la compréhension de leur mode d’action à l’échelle moléculaire représente une étape essentielle à l’identification de sondes biologiques du fonctionnement et du développement des organismes, en plus de faciliter la mise au point de dérivés potentiellement utiles comme outils pharmacologiques ou agents thérapeutiques.

Nos travaux ciblent certaines familles de peptides caractérisées entre autres par le rôle unique qu’elles jouent au niveau des systèmes nerveux, endocrinien et cardiovasculaire. Nous souhaitons ainsi mieux définir les fonctions biologiques associées à certaines familles de peptides dans des états physiologiques normaux et pathologiques. De plus, les composés polypeptidiques étudiés servent de modèles pour l’établissement de caractéristiques structurales et biologiques de base. Ensuite, des dérivés synthétiques comportant des modifications chimiques sont alors assemblés puis évalués biologiquement afin d’explorer plus à fond certains paramètres pharmacologiques des molécules.

Le Pr Alain Fournier a successivement obtenu à l’Université de Sherbrooke un baccalauréat en chimie-biochimie, une maîtrise en pharmacologie et un doctorat en chimie bioorganique. Après des études postdoctorales au Health Sciences Centre de l’Université de Calgary, puis au Roche Research Centre de Nutley, New Jersey, il est entré en fonction en 1987 à titre de professeur à l’INRS-Institut Armand-Frappier. Il a été successivement Chercheur-boursier Junior et Senior du Fonds de la recherche en santé du Québec, ainsi que Chercheur National de ce même organisme. Il a aussi été pendant plusieurs années professeur associé au Département de Pharmacologie de l’Université de Montréal ainsi qu’au Département de Pharmacologie de l’Université de Sherbrooke. De février 2006 à janvier 2008, il a été

Directeur intérimaire du centre INRS – Institut Armand-Frappier, pour par la suite devenir le directeur en titre jusqu’en septembre 2010. Après son mandat de directeur de centre, il est devenu Directeur scientifique de l’INRS. Il a occupé ce poste jusqu’en mars 2013. Il est ensuite redevenu professeur-chercheur et il a poursuivi ses activités de recherche en chimie médicinale et pharmacologie jusqu’en décembre 2016, moment où il a pris sa retraite et est devenu professeur honoraire de l’INRS.

Avec sa formation pluridisciplinaire en chimie, pharmacologie et biochimie, le Pr Fournier a oeuvré dans des champs de recherche exigeant la mise au point de méthodes de synthèse d’hormones polypeptidiques, leur évaluation structurale au moyen d’estimations théoriques et de techniques spectroscopiques, ainsi que la mesure de leurs propriétés pharmacologiques et biochimiques.

Son parcours lui a permis de recevoir divers prix et honneurs dont le Prix Adrien-Pouliot de l’ACFAS (2012) et le Prix Planète INRS (2015).

Le professeur Fournier a été codirecteur du Laboratoire international associé (LIA) Samuel de Champlain, mis sur pied dans le cadre d’un LIA supporté par l’Institut national de la santé et de la recherche médicale (INSERM) et de l’Institut national de la recherche scientifique (INRS). Les travaux ont focalisé  sur la pharmacologie et la biochimie des neuropeptides. Le codirecteur du côté français était le professeur Hubert Vaudry de l’Université de Rouen.

Avec sa formation pluridisciplinaire en chimie, pharmacologie et biochimie, le Pr Fournier a oeuvré dans des champs de recherche exigeant la mise au point de méthodes de synthèse d’hormones polypeptidiques, leur évaluation structurale au moyen d’estimations théoriques et de techniques spectroscopiques, ainsi que la mesure de leurs propriétés pharmacologiques et biochimiques. Son parcours lui a permis de recevoir divers prix et honneurs dont le Prix Adrien-Pouliot de l’ACFAS (2012) et le Prix Planète INRS (2015).

Brevets et brevets provisoires

1.  Preparation of polysulfated peptides as cholecystokinin-​8 analogs

By: Felix, Arthur M.; Fournier, Alain; Danho, Waleed

Assignee: Hoffmann-La Roche, Inc., USA

X-​(R)​n-​Tyr(SO3H)​-​R1-​R2-​R3-​R4-​R5-​MePhe-​Y [X = COR6, CO2R6, CO(CH2)​mMe, COCO2R7, CO(CH2)​mCO2R8; R = Asp, Arg; R1 = Met, Nle, Leu, null; R2 = Gly, Ala, D-​Ala, β-​Ala; R3 = Trp, Trp(CHO)​; R4 = Met, Nle, Nva, Pro; R5 = Thr(SO3H)​, Ser(SO3H)​, Hyp(SO3H)​; R6, R8, R9, R10 = H, alkyl; or R7 = R8 = H, (halo)​alkyl; Y = OR8, NR9R10; n = 0, 1; m = 1-​14] are prepd. by the solid phase method using benzotriazol-​1-​yloxy-​tris(dimethylamino)​phosphonium hexafluorophosphate (I) as a coupling reagent; the OH groups of hydroxyamino acids are not protected and side reactions during peptide synthesis are minimized by using 3 equiv of I and 3 equiv of N-​(tert-​butoxycarbonyl)​hydroxyamino acid in the coupling step.  Ac-​Tyr(SO3H)​-​Met-​Gly-​Trp-​Met-​Thr(SO3H)​-​Phe-​NH2 was prepd. using BOC-​Phe-​PAM resin (BOC = CO2CMe3)​, wherein the fully assembled peptide-​resin was sulfated by SO3·pyridine complex or pyridinium acetyl sulfate in pyridine.  Also prepd. was Ac-​Tyr(SO3H)​-​Nle-​Gly-​Trp-​Nle-​Thr(SO3H)​-​MePhe-​NH2.

Patent No : US 4965343    Date : Oct 23, 1990    Application No : US 1988-149261 Date : Jan 28, 1988

Priority Application: US 1988-149261   Date: Jan 28, 1988

2.  Labelled adrenomedullin derivatives and their use for imaging and therapy

By: Dupuis, Jocelyn; Fournier, Alain

Assignee: Institut de Cardiologie de Montreal, Can.

The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent.  Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others.  Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonnance Imaging (MRI)​.  Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent.  Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ.  If the organ is the lungs, a non-​limiting example of pathol. treatable with the fibrinolytic is pulmonary embolus.

Patent No. Kind Language Date Application No. Date
WO 2005116065 A1 Dec 8, 2005 WO 2005-CA791 May 24, 2005
CA 2567478 A1 Dec 8, 2005 CA 2005-2567478 May 24, 2005
CA 2567478 C Apr 1, 2014
EP 1749026 A1 Feb 7, 2007 EP 2005-748704 May 24, 2005
EP 1749026 B1 English Nov 23, 2011
AT 534664 T Dec 15, 2011 AT 2005-748704 May 24, 2005
US 20080274050 A1 Nov 6, 2008 US 2006-597315 Nov 21, 2006
US 8703098 B2 English Apr 22, 2014
US 20090028790 A1 English Jan 29, 2009 US 2008-149989 May 12, 2008
US 8475764 B2 English Jul 2, 2013
US 20120082619 A1 English Apr 5, 2012 US 2011-13067914 Jul 7, 2011
Priority Application
US 2004-60573334 P May 24, 2004
WO 2005-CA791 W May 24, 2005
US 2007-60924393 P May 11, 2007
US 2008-149989 A1 May 12, 2008

 

3.  Labelled adrenomedullin derivatives and their use for imaging and therapy.

By: Dupuis, Jocelyn; Fournier, Alain

Assignee: Institut de Cardiologie de Montreal, Can.

The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent.  Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others.  Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI)​. Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent.  Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ.  If the organ is the lungs, a non-​limiting example of pathol. treatable with the fibrinolytic agent is pulmonary embolus.

Patent No. Kind Language Date Application No.       Date
WO 2008138141 A1 Nov 20, 2008 WO 2008-CA934 May 12, 2008
CA 2686760 A1 Nov 20, 2008 CA 2008-2686760 May 12, 2008
EP 2155781 A1 Feb 24, 2010 EP 2008-757094 May 12, 2008
EP 2155781 B1 English Mar 13, 2013
 

Priority Application

US 2007-60924393 P May 11, 2007
WO 2008-CA934 W May 12, 2008

4.  Labelled adrenomedullin derivatives and their use for imaging and therapy

By: Dupuis, Jocelyn; Fournier, Alain

Assignee: Institut de Cardiologie de Montreal, Can.; Institut Nationale de la Recherche Scientifique

The present invention relates to an adrenomedullin deriv. including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent.  Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others.  Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI)​.  Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent.  Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ.  If the organ is the lungs, a non-​limiting example of pathol. treatable with the fibrinolytic agent is pulmonary embolus.

Patent No. Kind Language Date Application No. Date
US 20090028790 A1 Jan 29, 2009 US 2008-149989 May 12, 2008
US 8475764 B2 English Jul 2, 2013
WO 2005116065 A1 English Dec 8, 2005 WO 2005-CA791 May 24, 2005
US 20120082619 A1 English Apr 5, 2012 US 2011-13067914 Jul 7, 2011
Priority Application
US 2004-60573334 P May 24, 2004
WO 2005-CA791 A2 May 24, 2005
US 2007-60924393 P May 11, 2007
US 2008-149989 A1 May 12, 2008

 

5.  Novel agonists and antagonists of the urotensinergic system and their cardiovascular effects

By: Chatenet, David; Létourneau, Myriam; Fournier, Alain

Assignee: Institut National de la Recherche Scientifique, Can.

Novel urotensin II receptor (UT) agonists and antagonists are described herein.  More specifically, novel derivs. of urotensin II-​related peptide (URP) are described herein.  In an embodiment, the present disclosure relates to a urotensinergic agent or a pharmaceutical acceptable salt thereof having the formula: Ala-​Cys-​Phe-​X-​Lys-​Tyr-​Cys-​Val wherein X is an L-​or D-​amino acid and sidechain conformationally restricted phenylalanines, or a phenylalanine analog.  In an embodiment, the present disclosure relates to a method for discriminating between specific biol. action mediated by UII and​/or URP comprising the steps of: (i) exposing aortic rings to a urotensinergic agent as disclosed herein; (ii) prepg. concn.-​response curves to UII or URP; and (ii) evaluating the effect of the urotensinergic agent on aortic ring contraction induced by either UII or URP.  In a specific embodiment, the present disclosure relates to a biphenylalanine urotensin II-​related peptide ([Bip4]​URP i.e., urocontrin)​.

Patent No. Kind Language Date Application No. Date
WO 2012149644 A1 Nov 8, 2012 WO 2012-CA421 May 3, 2012
CA 2832464 A1 Nov 8, 2012 CA 2012-2832464 May 3, 2012
AU 2012250462 A1 Nov 7, 2013 AU 2012-250462 May 3, 2012
EP 2729184 A1 May 14, 2014 EP 2012-779758 May 3, 2012
JP 2014518854 T Japanese Aug 7, 2014 JP 2014-508657 May 3, 2012
US 2014011387 A1 English Apr 24, 2014 US 2014-14114757 Jan 9, 2014
Priority Application
US 2011-61481985 P May 3, 2011
WO 2012-CA421 W May 3, 2012

Développement de dérivés neuroprotecteurs du pituitary adenylate cyclase-activating polypeptide (PACAP)

Le neuropeptide PACAP exerce une forte activité protectrice contre la neurodégénérescence dans certains modèles physiopathologiques d’atteintes du cerveau tels l’AVC et le Parkinson. Plus particulièrement, lorsqu’injecté après un choc ischémique, le PACAP peut stopper l’expansion de la zone infarcie dans les régions cérébrales lésées. Toutefois, à cause de sa nature peptidique, cette substance possède des propriétés pharmacocinétiques qui limitent son utilisation comme agent thérapeutique. Donc, dans le cadre de nos études, en collaboration avec des chercheurs de l’Université de Rouen (FR), des analogues du PACAP ont été synthétisés dans le but de leur procurer une stabilité métabolique accrue et d’améliorer leur sélectivité d’action.

Développement de dérivés de l’adrénomédulline (AM) humaine capables de chélater un radioisotope et de servir en imagerie pulmonaire

La médecine nucléaire utilise actuellement les macroaggrégats d’albumine (MAA) comme traceurs de la circulation dans les poumons. Malheureusement, la taille de ces composés ne permet pas la visualisation de la microcirculation pulmonaire ce qui nuit au diagnostic précoce. En collaboration avec une équipe de recherche de l’Institut de cardiologie de Montréal, nous avons montré que l’adrénomédulline (AM), un peptide de 52 acides aminés, est capable de chélater certains radioisotopes et que le complexe ainsi formé possède une affinité très significative pour les poumons. Bien que ce nouvel outil d’imagerie offrait l’avantage d’être plus petit que les MAA, il n’était pas encore optimal. De plus, la longueur du peptide constituait un défi sérieux pour une production facile et un usage clinique courant. Depuis, nous avons réussi à produire un dérivé, le PulmoBind, qui a traversé les étapes des phases cliniques I et II.


Caractérisation structurale et pharmacologique du peptide
urotensine II et de son récepteur UT

L’urotensine II (UII) est un peptide présent dans divers systèmes biologiques dont les systèmes nerveux et cardiovasculaires. Au niveau de ce dernier, il a été montré que certains tissus étaient très sensibles à UII puisque des contractions des muscles lisses vasculaires peuvent être induites à des concentrations de ligand de l’ordre du picomolaire. Cet effet nous a amenés à explorer à l’échelle moléculaire le mode d’interaction du peptide UII avec son récepteur membranaire appelé UT.

Identification et caractérisation de peptides bioactifs isolés à partir du venin d’un cobra d’Asie du Sud-Est

Dans le cadre d’une collaboration avec des partenaires du Vietnam, nous avons évalué les propriétés biologiques de dérivés peptidiques isolés du venin d’un cobra retrouvé en Asie du Sud-Est. Le venin est un cocktail complexe de nombreuses molécules aux activités diverses au niveau des systèmes physiologiques. Nos travaux ont permis l’isolation et la caratérisation d’un peptide capable d’induire la sécrétion d’insuline. De plus, au moyen d’études structurales, la molécule a été amélioriée et elle constitue un canevas prometteur pour la mise au point d’un nouvel agent thérapeutique.

Publications

414. LAMINE, A., POUJOL DE MOLLIENS, M., LÉTOURNEAU, M., HÉBERT, T.E., VAUDRY, D., FOURNIER, A. & CHATENET, D. (2019)

The amidated PACAP1-23 fragment is a potent reduced-size neuroprotective agent,

Biochimica Biophysica Acta (General Subjects), 1863, 129410, doi: 10.1016/j.bbagen.2019.08.003

 

413. POUJOL DE MOLLIENS, M., JAMADAGNI, P., LÉTOURNEAU, M., DEVOST, D., HÉBERT, T.E., PATTEN, S.A., FOURNIER, A. & CHATENET, D. (2019)

Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor,

Biochimica Biophysica Acta (General Subjects), 1863, 129398, doi: 10.1016/j.bbagen.2019.07.007

 

412. ALONSO MARTINEZ, L.M., HAREL, F., LÉTOURNEAU, M., FINNERTY, V., FOURNIER, A., DUPUIS, J. & DASILVA, J.N. (2019)

SPECT and PET imaging of adrenomedullin receptors: a promising strategy for studying pulmonary vascular diseases,

American Journal of Nuclear Medicine and Molecular Imaging, 9, 203-215

 

411. MERABET, N., NSAIBIA, M.J., NGUYEN, Q.T., SHI, Y.F., LÉTOURNEAU, M., FOURNIER, A., TARDIF, J.C., HAREL, F. & DUPUIS, J. (2019)

PulmoBind imaging measures reduction of vascular adrenomedullin receptor activity with lack of effect of Sildenafil in pulmonary hypertension,

Scientific Reports (Nature), 9, 6609, doi: 10.1038/s41598-019-43225-3

 

410. ALONSO MARTINEZ, L.M., HAREL, F., NGUYEN, Q.T., LÉTOURNEAU, M., D’OLIVIERA-SOUSA, C., MELOCHE, B., FINNERTY, V., FOURNIER, A., DUPUIS, J. & SASILVA, J.N. (2018)

Al18F-complexation of DFH17, a NOTA-conjugated adrenomedullin analog, for PET imaging of pulmonary circulation,

Nuclear Medicine and Biology, 67, 36-42

 

409. POUJOL DE MOLLIENS, M., LÉTOURNEAU, M., DEVOST, D., HÉBERT, TE., FOURNIER, A. & CHATENET, D. (2018)

New insights about the peculiar role of the 28-38 C-terminal segment and some selected residues in PACAP for signaling and neuroprotection,

Biochemical Pharmacology, 154, 193-202

 

408. CABEZAS-LLOBET, N., VIDAL-SANCHO, L., MASANA, M., FOURNIER, A., ALBERCH, J., VAUDRY, D. & XIFRÓ, X. (2018)

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington’s Disease,

Molecular Neurobiology, 55, 8263-8277

 

407.TADEVOSYAN, A., XIAO, J., SURINKAEW, S., NAUD, P., MERLEN, C., HARADA, M., XIAO, Y.Q., CHATENET, D., FOURNIER, A., ALLEN, B. & NATTEL, S. (2017)

Intracellular Angiotensin-II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion,

Journal of the American Heart Association, 6(4), pii: e004965, doi: 10.1161/JAHA.116.004965

 

406. HAREL, F., LANGLEBEN, D., PROVENCHER, S., FOURNIER, A., FINNERTY, V., NGUYEN, Q.T., LÉTOURNEAU, M., LEVAC, X., ABIKHZER, G., GUIMOND, J., MANSOUR, A., GUERTIN, M.-C. & DUPUIS, J. (2017)

Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial,

European Journal of Nuclear Medicine and Molecular Imaging, 44, 1136-1144

 

405. CHATENET, D., FOURNIER, A. & BOURGAULT, S. (2016)

PACAP-derived carriers: Mechanisms and applications,

Pituitary Adenylate Cyclase Activating Polypeptide — PACAP,

D. Reglodi & A. Tamas Ed, Springer, 133-148

 

404.FOURNIER, A., BOURGAULT, S. & CHATENET, D. (2016)

The pharmacophoric determinants of PACAP,

Pituitary Adenylate Cyclase Activating Polypeptide — PACAP,

D. Reglodi & A. Tamas Ed, Springer, 111-132

 

403.LEVAC, X., HAREL, F., FINNERTY, V., NGUYEN, Q.T., LÉTOURNEAU, M., MARCIL, S., FOURNIER, A. & DUPUIS, J. (2016)

Evaluation of pulmonary perfusion by SPECT imaging using an endothelial cell tracer in supine humans and dogs,

European Journal of Nuclear Medicine and Molecular Imaging Research, 6(43), 1-9

 

402.THERRIEN, A., FOURNIER, A. & LAFLEUR, M. (2016)

Role of the Cationic C-Terminal Segment of Melittin on Membrane Fragmentation,

The Journal of Physical Chemistry – B, 110, 400-410

 

401.DOUIRI, S., BAHDOUDI, S., HAMDI, Y., CUBI, RT., BASILLE, M., FOURNIER, A., VAUDRY, H., TONON, M.C., AMRI, M., VAUDRY, D. & MASMOUDI-KOUKI, O. (2016)

Involvement of endogenous antioxidant systems in the protective activity of pituitary adenylate cyclase-activating polypeptide against hydrogen peroxide-induced oxidative damages in cultured rat astrocytes,

Journal of Neurochemistry, 137, 913-930

 

400.De BOISVILLIERS, M.D., PERRIN, F., HEBACHE, S., BALANDRE, A.C., BENSALMA, S., GARNIER, A., VAUDRY, D., FOURNIER, A., FESTY, F., MULLER, J.M. & CHARDÉNEAU, C. (2016)

VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells,

 

Peptides, 78, 30-41

 

399.LAMINE-AJILI, A., FAHMY, A. M., LÉTOURNEAU, M., CHATENET, D., LABONTÉ, P., VAUDRY, D. & FOURNIER, A. (2016)

Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson’s disease,

Biochimica et Biophysica Acta – Molecular Basis of Disease, 1862, 688-695

 

398.TADEVOSYAN, A., VILLENEUVE, L. R., FOURNIER, A., CHATENET, D., NATTEL, S. & ALLEN, B. G. (2016)

Caged ligands to study the role of intracellular GPCRs,

Methods, 92, 72-77

 

397.LAMINE, A., LÉTOURNEAU, M., DOAN, N. D., MAUCOTEL, J., COUVINEAU, A., VAUDRY, H., CHATENET, D., VAUDRY, D. & FOURNIER, A. (2016)

Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson’s disease model,

Neuropharmacology, 108, 440-450

 

396.CHATENET, D., BOURGAULT, S. & FOURNIER, A. (2015)

Design and application of light-activated probes for cellular signaling,

Methods in Molecular Biology, 1234, 17-30

 

395.VAUDRY, H., LEPRINCE, J., CHATENET, D., FOURNIER, A., LAMBERT, D. G., LE MEVEL, J. C., OHLSTEIN, E. H., SCHWERTANI, A., TOSTIVINT, H. & VAUDRY, D. (2015)

International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II-Related Peptide, and Their Receptor: From Structure to Function,

Pharmacological Reviews, 67, 1, 214-58

 

394.HAREL, F., LEVAC, X., NGUYEN, Q. T., LÉTOURNEAU, M., MARCIL, S., FINNERTY, V., COSSETTE, M., FOURNIER, A. & DUPUIS, J. (2015)

Molecular imaging of the human pulmonary vascular endothelium using an adrenomedullin receptor ligand,

Molecular Imaging, 14, 1-13

 

393.TADEVOSYAN, A., LÉTOURNEAU, M., FOLCH, B., DOUCET, N., VILLENEUVE, L. R., MAMARBACHI, A. M., PÉTRIN, D., HÉBERT, T. E., FOURNIER, A., CHATENET, D., ALLEN, B. G. & NATTEL, S. (2015)

Photoreleasable ligands to study intracrine angiotensin II signalling,

Journal of Physiology, 593, 3, 521-539

 

392. JOLIVEL, V., ARTHAUD, S., BOTIA, B., PORTAL, C., DELEST, B., CLAVÉ, G., LEPRINCE, J., ROMIEU, A., RENARD, P. Y., TOUZANI, O., LIGERET, H., NOACK, P., MASSONNEAU, M., FOURNIER, A., VAUDRY, H. & VAUDRY, D. (2014)

Biochemical Characterization of a Caspase-3 Far-red Fluorescent Probe for Non-invasive Optical Imaging of Neuronal Apoptosis,

Journal of Molecular Neuroscience, 54, 3, 451-462

 

391.SEABORN, T., RAVNI, A., AU, R., CHOW, B. K. C., FOURNIER, A., WURTZ, O., VAUDRY, H., EIDEN, L. E. & VAUDRY, D. (2014)

Induction of serpinb1a by PACAP or NGF is required for PC12 cells survival after serum withdrawal,

Journal of Neurochemistry, 131, 1, 21-32

 

390.TCHOUMI NEREE, A., NGUYEN, P. T., CHATENET, D., FOURNIER, A. & BOURGAULT, S. (2014)

Secondary conformational conversion is involved in glycosaminoglycans-mediated cellular uptake of the cationic cell-penetrating peptide PACAP,

FEBS Letters, 588, 24, 4590-4596

 

389. RAOULT, E., BÉNARD, M., KOMURO, H., LEBON, A., VIVIEN, D., FOURNIER, A., VAUDRY, H., VAUDRY, D. & GALAS, L. (2014)

Cortical-layer-specific effects of PACAP and tPA on interneuron migration during post-natal development of the cerebellum,

Journal of Neurochemistry, 130, 2, 241-254

 

388. NGUYEN, T. T., FOLCH, B., LETOURNEAU, M., TRUONG, N. H., DOUCET, N., FOURNIER, A. & CHATENET, D. (2014)

Design of a truncated cardiotoxin-I analogue with potent insulinotropic activity,

Journal of Medicinal Chemistry, 57, 6, 2623-33

 

387.CHATENET, D., FOLCH, B., FEYTENS, D., LÉTOURNEAU, M., TOURWÉ, D., DOUCET, N. & FOURNIER, A. (2013)

Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists,

Journal of Medicinal Chemistry, 56, 23, 9612-9622

 

386.VAUDRY, D., NAKAMACHI, T., BASILLE, M., WURTZ, O., FOURNIER, A., VAUDRY, H. & SHOIDA, S. (2013)

PACAPHandbook of Biologically Active Peptides Second Edition ed., 889-897

 

385. VAUDRY, D., BUREL, D., GALAS, L., LACAILLE, H., DUTERTE-BOUCHER, D., CHATENET, D., FOURNIER, A. & VAUDRY, H. (2013)

PACAPHandbook of Biologically Active Peptides Second Edition ed., 1038-1043

 

384. BASILLE-DUGAY, M., VAUDRY, H., FOURNIER, A., GONZALEZ, B. & VAUDRY, D. (2013)

Activation of PAC1 receptors in rat cerebellar granule cells stimulates both calcium mobilization from intracellular stores and calcium influx through N-type calcium channels,

Frontiers in Endocrinology, 4, MAY,

 

383. VANIOTIS, G., GLAZKOVA, I., MERLEN, C., SMITH, C., VILLENEUVE, L. R., CHATENET, D., THERIEN, M., FOURNIER, A., TADEVOSYAN, A., TRIEU, P., NATTEL, S., HÉBERT, T. E. & ALLEN, B. G. (2013)

Regulation of cardiac nitric oxide signaling by nuclear β-adrenergic and endothelin receptors,

Journal of Molecular and Cellular Cardiology, 62, 58-68

 

382. MERLEN, C., FARHAT, N., LUO, X., CHATENET, D., TADEVOSYAN, A., VILLENEUVE, L. R., GILLIS, M. A., NATTEL, S., THORIN, E., FOURNIER, A. & ALLEN, B. G. (2013)

Intracrine endothelin signaling evokes IP3-dependent increases in nucleoplasmic Ca2+ in adult cardiac myocytes,

Journal of Molecular and Cellular Cardiology, 62, 189-202

 

381. LETOURNEAU, M., NGUYEN, Q. T., HAREL, F., FOURNIER, A. & DUPUIS, J. (2013)

PulmoBind, an Adrenomedullin-Based Molecular Lung Imaging Tool,

Journal of Nuclear Medicine, 54, 10, 1789-96

 

380. CHATENET, D., LÉTOURNEAU, M., NGUYEN, Q. T., DOAN, N. D., DUPUIS, J. & FOURNIER, A. (2013)

Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: Insight into UII and URP receptor activation,

British Journal of Pharmacology, 168, 4, 807-821

 

379. FOURNIER, A., CHATENET, D. & LETOURNEAU, M. (2012)

Novel agonists and antagonists of the urotensinergic system and their cardiovascular effectsCopyright (C) 2013 American Chemical Society (ACS). All Rights Reserved., 86pp.

 

378. DOAN, N. D., LÉTOURNEAU, M., VAUDRY, D., DOUCET, N., FOLCH, B., VAUDRY, H., FOURNIER, A. & CHATENET, D. (2012)

Design and characterization of novel cell-penetrating peptides from pituitary adenylate cyclase-activating polypeptide,

Journal of Controlled Release, 163, 2, 256-265

 

377. NGUYEN, T. T. N., FOLCH, B., LÉTOURNEAU, M., VAUDRY, D., TRUONG, N. H., DOUCET, N., CHATENET, D. & FOURNIER, A. (2012)
Cardiotoxin-I: An Unexpectedly Potent Insulinotropic Agent .
Chembiochem , 13, 12, 1805-1812
376. DOAN, N. D., NGUYEN, T. T. M., LETOURNEAU, M., TURCOTTE, K., FOURNIER, A. & CHATENET, D. (2012)
Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart .
British Journal of Pharmacology , 166, 1, 243-257
375. NGUYEN, T. T., LÉTOURNEAU, M., CHATENET, D. & FOURNIER, A. (2012)
Presence of urotensin-II receptors at the cell nucleus: Specific tissue distribution and hypoxia-induced modulation .
International Journal of Biochemistry and Cell Biology , 44, 4, 639-47
374. DOAN, N. D., CHATENET, D., LÉTOURNEAU, M., VAUDRY, H., VAUDRY, D. & FOURNIER, A. (2012)
Receptor-independent cellular uptake of pituitary adenylate cyclase-activating polypeptide .
Biochimica et Biophysica Acta , 1823, 4, 940-949
373. CHATENET, D., NGUYEN, Q.-T., LETOURNEAU, M., DUPUIS, J. & FOURNIER, A. (2012)
Urocontrin, a novel UT receptor ligand with a unique pharmacological profile .
Biochemical Pharmacology , 83, 5, 608-615
372. TAM, J. K., LAU, K. W., LEE, L. T., CHU, J. Y., NG, K. M., FOURNIER, A., VAUDRY, H. & CHOW, B. K. (2011)
Origin of secretin receptor precedes the advent of tetrapoda: evidence on the separated origins of secretin and orexin .
PLoS ONE , 6, 4, e19384
371. SEABORN, T., MASMOUDI-KOULI, O., FOURNIER, A., VAUDRY, H. & VAUDRY, D. (2011)
Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis .
Current Pharmaceutical Design , 17, 3, 204-14
370. RAOULT, E., ROUSSEL, B. D., BENARD, M., LEFEBVRE, T., RAVNI, A., ALI, C., VIVIEN, D., KOMURO, H., FOURNIER, A., VAUDRY, H., VAUDRY, D. & GALAS, L. (2011)
Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates the expression and the release of tissue plasminogen activator (tPA) in neuronal cells: involvement of tPA in the neuroprotective effect of PACAP .
Journal of Neurochemistry , 119, 5, 920-931
369. MASMOUDI-KOUKI, O., DOUIRI, S., HAMDI, Y., KADDOUR, H., BAHDOUDI, S., VAUDRY, D., BASILLE, M., LEPRINCE, J., FOURNIER, A., VAUDRY, H., TONON, M. C. & AMRI, M. (2011)
Pituitary adenylate cyclase-activating polypeptide protects astroglial cells against oxidative stress-induced apoptosis .
Journal of Neurochemistry , 117, 3, 403-11
368. FU, Y., LÉTOURNEAU, M., CHATENET, D., DUPUIS, J. & FOURNIER, A. (2011)
Characterization of iodinated adrenomedullin derivatives suitable for lung nuclear medicine .
Nuclear Medicine and Biology , 38, 6, 867-74
367. EL KEBIR, D., ZHANG, Y., POTEMPA, L. A., WU, Y., FOURNIER, A. & FILEP, J. G. (2011)
C-reactive protein-derived peptide 201-206 inhibits neutrophil adhesion to endothelial cells and platelets through CD32 .
Journal of Leukocyte Biology , 90, 6, 1167-1175
366. DOAN, N. D., NGUYEN, T. T., LETOURNEAU, M., TURCOTTE, K., FOURNIER, A. & CHATENET, D. (2011)
Biochemical and Pharmacological Characterization of Nuclear Urotensin II Binding Sites in Rat Heart .
British Journal of Pharmacology ,
365. DOAN, N. D., BOURGAULT, S., DEJDA, A., LETOURNEAU, M., DETHEUX, M., VAUDRY, D., VAUDRY, H., CHATENET, D. & FOURNIER, A. (2011)
Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects .
Biochemical Pharmacology , 81, 4, 552-561
364. DEJDA, A., SEABORN, T., BOURGAULT, S., TOUZANI, O., FOURNIER, A., VAUDRY, H. & VAUDRY, D. (2011)
PACAP and a novel stable analog protect rat brain from ischemia: Insight into the mechanisms of action .
Peptides , 32, 6, 1207-1216
363. DEJDA, A., BOURGAULT, S., DOAN, N. D., LETOURNEAU, M., COUVINEAU, A., VAUDRY, H., VAUDRY, D. & FOURNIER, A. (2011)
Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP .
Biochimie , 93, 4, 669-677
362. BOURGAULT, S., CHATENET, D., WURTZ, O., DOAN, N. D., LEPRINCE, J., VAUDRY, H., FOURNIER, A. & VAUDRY, D. (2011)
Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug .
Current Pharmaceutical Design , 17, 10, 1002-1024
361. BOTIA, B., JOLIVEL, V., BUREL, D., LE JONCOUR, V., ROY, V., NAASSILA, M., BENARD, M., FOURNIER, A., VAUDRY, H. & VAUDRY, D. (2011)
Neuroprotective effects of PACAP against ethanol-induced toxicity in the developing rat cerebellum .
Neurotoxicity Research , 19, 3, 423-34
360. VAUDRY, H., DO REGO, J. C., LE MEVEL, J. C., CHATENET, D., TOSTIVINT, H., FOURNIER, A., TONON, M. C., PELLETIER, G., MICHAEL CONLON, J. & LEPRINCE, J. (2010)
Urotensin II, from fish to human .
Annals of the New York Academy of Sciences , 1200, 53-66
359. DOAN, N. D., BOURGAULT, S., DEJDA, A., LÉTOURNEAU, M., DETHEUX, M., VAUDRY, D., VAUDRY, H., CHATENET, D. & FOURNIER, A. (2010)
Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects .
Biochemical Pharmacology , Article in Press,
358. DEJDA, A., CHAN, P., SEABORN, T., COQUET, L., JOUENNE, T., FOURNIER, A., VAUDRY, H. & VAUDRY, D. (2010)
Involvement of stathmin 1 in the neurotrophic effects of PACAP in PC12 cells .
Journal of Neurochemistry , 114, 5, 1498-510
357. ALLAIS, A., BUREL, D., ROY, V., ARTHAUD, S., GALAS, L., ISAAC, E. R., DESFEUX, A., PARENT, B., FOURNIER, A., CHAPILLON, P., SHERWOOD, N. M., VAUDRY, H. & GONZALEZ, B. J. (2010)
Balanced effect of PACAP and FasL on granule cell death during cerebellar development: a morphological, functional and behavioural characterization .
Journal of Neurochemistry , 113, 2, 329-340
356. VAUDRY, D., FALLUEL-MOREL, A., BOURGAULT, S., BASILLE, M., BUREL, D., WURTZ, O., FOURNIER, A., CHOW, B. K. C., HASHIMOTO, H., GALAS, L. & VAUDRY, H. (2009)
Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 Years after the discovery .
Pharmacological Reviews , 61, 3, 283-357
355. MOUNIEN, L., DO REGO, J. C., BIZET, P., BOUTELET, I., GOURCEROL, G., FOURNIER, A., BRABET, P., COSTENTIN, J., VAUDRY, H. & JÉGOU, S. (2009)
Pituitary adenylate cyclase-activating polypeptide inhibits food intake in mice through activation of the hypothalamic melanocortin system .
Neuropsychopharmacology , 34, 2, 424-435
354. LEFEBVRE, T., GONZALEZ, B. J., VAUDRY, D., DESRUES, L., FALLUEL-MOREL, A., AUBERT, N., FOURNIER, A., TONON, M. C., VAUDRY, H. & CASTEL, H. (2009)
Paradoxical effect of ethanol on potassium channel currents and cell survival in cerebellar granule neurons .
Journal of Neurochemistry , 110, 3, 976-989
353. JOLIVEL, V., BASILLE, M., AUBERT, N., DE JOUFFREY, S., ANCIAN, P., LE BIGOT, J. F., NOACK, P., MASSONNEAU, M., FOURNIER, A., VAUDRY, H., GONZALEZ, B. J. & VAUDRY, D. (2009)
Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates .
Neuroscience , 160, 2, 434-451
352. HONG, Y., LIU, Y., CHABOT, J. G., FOURNIER, A. & QUIRION, R. (2009)
Upregulation of adrenomedullin in the spinal cord and dorsal root ganglia in the early phase of CFA-induced inflammation in rats .
Pain , 146, 1-2, 105-113
351. FU, Y., LÉTOURNEAU, M., NGUYEN, Q. T., CHATENET, D., DUPUIS, J. & FOURNIER, A. (2009)
Characterization of the adrenomedullin receptor acting as the target of a new radiopharmaceutical biomolecule for lung imaging .
European Journal of Pharmacology , 617, 1-3, 118-123
350. DUPUIS, J., HAREL, F., FU, Y., QUANG, T. N., LÉTOURNEAU, M., PRÉFONTAINE, A. & FOURNIER, A. (2009)
Molecular imaging of monocrotaline-induced pulmonary vascular disease with radiolabeled linear adrenomedullin .
Journal of Nuclear Medicine , 50, 7, 1110-1115
349. CHATENET, D., LÉTOURNEAU, M. & FOURNIER, A. (2009)
Design, Synthesis and Biological Activities of New Urotensin Ii-Related Peptides (Urp) .
Proceedings of the Twenty-First American Peptide Symposium June 7-12, 2009, Bloomington, IN, U.S.A. , 133-134
348. BOURGAULT, S., VAUDRY, D., SÉGALAS-MILAZZO, I., GUILHAUDIS, L., COUVINEAU, A., LABURTHE, M., VAUDRY, H. & FOURNIER, A. (2009)
Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor .
Journal of Medicinal Chemistry , 52, 10, 3308-3316
347. BOURGAULT, S., VAUDRY, D., DEJDA, A., DOAN, N. D., VAUDRY, H. & FOURNIER, A. (2009)
Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide .
Current Medicinal Chemistry , 16, 33, 4462-80
346. ZHOKHOV, S. S., DESFEUX, A., AUBERT, N., FALLUEL-MOREL, A., FOURNIER, A., LAUDENBACH, V., VAUDRY, H. & GONZALEZ, B. J. (2008)
Bax siRNA promotes survival of cultured and allografted granule cell precursors through blockade of caspase-3 cleavage .
Cell Death and Differentiation , 15, 6, 1042-1053
345. PARAT, M., MCNICOLL, N., WILKES, B., FOURNIER, A. & DE LÉAN, A. (2008)
Role of extracellular domain dimerization in agonist-induced activation of natriuretic peptide receptor A .
Molecular Pharmacology , 73, 2, 431-440
344. LEPRINCE, J., CHATENET, D., DUBESSY, C., FOURNIER, A., PFEIFFER, B., SCALBERT, E., RENARD, P., PACAUD, P., OULYADI, H., SÉGALAS-MILAZZO, I., GUILHAUDIS, L., DAVOUST, D., TONON, M. C. & VAUDRY, H. (2008)
Structure-activity relationships of urotensin II and URP .
Peptides , 29, 5, 658-673
343. HAREL, F., FU, Y., NGUYEN, Q. T., LÉTOURNEAU, M., PERRAULT, L. P., CARON, A., FOURNIER, A. & DUPUIS, J. (2008)
Use of adrenomedullin derivatives for molecular imaging of pulmonary circulation .
Journal of Nuclear Medicine , 49, 11, 1869-1874
342. GRUMOLATO, L., GHZILI, H., MONTERO-HADJADJE, M., GASMAN, S., LESAGE, J., TANGUY, Y., GALAS, L., AIT-ALI, D., LEPRINCE, J., GUÉRINEAU, N. C., ELKAHLOUN, A. G., FOURNIER, A., VIEAU, D., VAUDRY, H. & ANOUAR, Y. (2008)
Selenoprotein T is a PACAP-regulated gene involved in intracellular Ca 2+ mobilization and neuroendocrine secretion .
Faseb Journal , 22, 6, 1756-1768
341. DOAN, N. D., BOURGAULT, S., LÉTOURNEAU, M. & FOURNIER, A. (2008)
Effectiveness of the Suzuki – Miyaura cross-coupling reaction for solid-phase peptide modification .
Journal of Combinatorial Chemistry , 10, 1, 44-51
340. DEJDA, A., JOLIVEL, V., BOURGAULT, S., SEABORN, T., FOURNIER, A., VAUDRY, H. & VAUDRY, D. (2008)
Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: A better understanding towards therapeutic applications in neurodegenerative diseases .
Journal of Molecular Neuroscience , 36, 1-3, 26-37
339. BOURGAULT, S., VAUDRY, D., GUILHAUDIS, L., RAOULT, É., COUVINEAU, A., LABURTHE, M., SÉGALAS-MILAZZO, I., VAUDRY, H. & FOURNIER, A. (2008)
Biological and structural analysis of truncated analogs of PACAP27 .
Journal of Molecular Neuroscience , 36, 1-3, 260-269
338. BOURGAULT, S., VAUDRY, D., BOTIA, B., COUVINEAU, A., LABURTHE, M., VAUDRY, H. & FOURNIER, A. (2008)
Novel stable PACAP analogs with potent activity towards the PAC1 receptor .
Peptides , 29, 6, 919-932
337. BOTIA, B., SEYER, D., RAVNI, A., BÉNARD, M., FALLUEL-MOREL, A., COSETTE, P., JOUENNE, T., FOURNIER, A., VAUDRY, H., GONZALEZ, B. J. & VAUDRY, D. (2008)
Peroxiredoxin 2 is involved in the neuroprotective effects of PACAP in cultured cerebellar granule neurons .
Journal of Molecular Neuroscience , 36, 1-3, 61-72
336. BOIVIN, S., SÉGALAS-MILAZZO, I., GUILHAUDIS, L., OULYADI, H., FOURNIER, A. & DAVOUST, D. (2008)
Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II. .
Peptides , 29, 5, 700-710
335. AUBIN, J., LÉTOURNEAU, M., FRANCOEUR, E., BURGEON, E. & FOURNIER, A. (2008)
Identification of ETA and ETB binding domains using ET-derived photoprobes .
Biochimie , 90, 6, 918-929
334. AUBERT, N., VAUDRY, D., FALLUEL-MOREL, A., DESFEUX, A., FISCH, C., ANCIAN, P., DE JOUFFREY, S., LE BIGOT, J. F., COUVINEAU, A., LABURTHE, M., FOURNIER, A., LAUDENBACH, V., VAUDRY, H. & GONZALEZ, B. J. (2008)
PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: Involvement of the mitochondrial apoptotic pathway .
Neurobiology of Disease , 32, 1, 66-80
333. VIAU, M., LÉTOURNEAU, M., SIROIS-DESLONGCHAMPS, A., BOULANGER, Y. & FOURNIER, A. (2007)
Study of solid-phase synthesis and purification strategies for the preparation of polyglutamine peptides .
Biopolymers , 88, 5, 754-763
332. OKADA, R., YAMAMOTO, K., ITO, Y., MOCHIDA, H., TONON, M. C., FOURNIER, A., LEPRINCE, J., VAUDRY, H. & KIKUYAMA, S. (2007)
VIP and PACAP stimulate TSH release from the bullfrog pituitary .
Peptides , 28, 9, 1784-1789
331. MASMOUDI-KOUKI, O., GANDOLFO, P., CASTEL, H., LEPRINCE, J., FOURNIER, A., DEJDA, A., VAUDRY, H. & TONON, M. C. (2007)
Role of PACAP and VIP in astroglial functions .
Peptides , 28, 9, 1753-1760
330. LEGROS, E., TIRAPELLI, C. R., CARRIER, E., BROCHU, I., FOURNIER, A. & D’ORLÉANS-JUSTE, P. (2007)
Characterization of the non-adrenergic/noncholinergic response to perivascular nerve stimulation in the double-perfused mesenteric bed of the mouse .
British Journal of Pharmacology , 152, 7, 1049-1059
329. FALLUEL-MOREL, A., CHAFAI, M., VAUDRY, D., BASILLE, M., CAZILLIS, M., AUBERT, N., LOUISET, E., DEJOUFFREY, S., LE BIGOT, J. F., FOURNIER, A., GRESSENS, P., ROSTÈNE, W., VAUDRY, H. & GONZALES, B. (2007)
The neuropeptide pituitary adenylate cyclase-activating polypeptide exerts anti-apoptotic and differentiating effects during neurogenesis: Focus on cerebellar granule neurones and embryonic stem cells .
Journal of Neuroendocrinology , 19, 5, 321-327
328. DUMONT, Y., MOYSE, E., FOURNIER, A. & QUIRION, R. (2007)
Distribution of peripherally injected peptide YY ([125I] PYY (3-36)) and pancreatic polypeptide ([125I] hPP) in the CNS: enrichment in the area postrema .
Journal of Molecular Neuroscience , 33, 3, 294-304
327. DE MONTGOLFIER, B., DUFRESNE, J., LÉTOURNEAU, M., NAGLER, J. J., FOURNIER, A., AUDET, C. & CYR, D. G. (2007)
The expression of multiple connexins throughout spermatogenesis in the rainbow trout testis suggests a role for complex intercellular communication .
Biology of Reproduction , 76, 1, 2-8
326. BOURGAULT, S., LÉTOURNEAU, M. & FOURNIER, A. (2007)
Development of photolabile caged analogs of endothelin-1 .
Peptides , 28, 5, 1074-1082
325. BOTIA, B., BASILLE, M., ALLAIS, A., RAOULT, E., FALLUEL-MOREL, A., GALAS, L., JOLIVEL, V., WURTZ, O., KOMURO, H., FOURNIER, A., VAUDRY, H., BUREL, D., GONZALEZ, B. J. & VAUDRY, D. (2007)
Neurotrophic effects of PACAP in the cerebellar cortex .
Peptides , 28, 9, 1746-52
324. AUBERT, N., BASILLE, M., FALLUEL-MOREL, A., VAUDRY, D., BUCHARLES, C., JOLIVEL, V., FISCH, C., DE JOUFFREY, S., LE BIGOT, J. F., FOURNIER, A., VAUDRY, H. & GONZALEZ, B. J. (2007)
Molecular, cellular, and functional characterizations of pituitary adenylate cyclase-activating polypeptide and its receptors in the cerebellum of new and old world monkeys .
Journal of Comparative Neurology , 504, 4, 427-439
323. VAUDRY, D., RAVNI, A., WURTZ, O., BÉNARD, M., BOTIA, B., JOLIVEL, V., FOURNIER, A., GONZALEZ, B. J. & VAUDRY, H. (2006)
Effects of PACAP in the local regulation of endocrine glands. .
Handbook of Biologically Active Peptides. London, Academic Press.

 

322. VALLARINO, M., BRUZZONE, F., MATHIEU, M., CHARTREL, N., VIEAU, D., CIARLO, M., FOURNIER, A. & VAUDRY, H. (2006)
Ontogeny of the somatostatin variant [Pro2,Met 13]somatostatin-14 in the brain, pituitary, and sensory organs of the frog Rana esculenta .
Journal of Comparative Neurology , 497, 5, 717-733
321. TAKHSHID, M. A., POYNER, D. R., CHABOT, J. G., FOURNIER, A., MA, W. Y., ZHENG, W. H., OWJI, A. A. & QUIRION, R. (2006)
Characterization and effects on cAMP accumulation of adrenomedullin and calcitonin gene-related peptide (CGRP) receptors in dissociated rat spinal cord cell culture .
British Journal of Pharmacology , 148, 4, 459-468
320. RAVNI, A., BOURGAULT, S., LEBON, A., CHAN, P., GALAS, L., FOURNIER, A., VAUDRY, H., GONZALEZ, B., EIDEN, L. E. & VAUDRY, D. (2006)
The neurotrophic effects of PACAP in PC12 cells: Control by multiple transduction pathways .
Journal of Neurochemistry , 98, 2, 321-329
319. OKADA, R., YAMAMOTO, K., ITO, Y., CHARTREL, N., LEPRINCE, J., FOURNIER, A., VAUDRY, H. & KIKUYAMA, S. (2006)
Effects of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide, and somatostatin on the release of thyrotropin from the bullfrog pituitary .
Vip, Pacap, and Related Peptides: From Gene to Therapy , 1070, 474-480
318. MOUNIEN, L., BIZET, P., BOUTELET, I., GOURCEROL, G., FOURNIER, A., VAUDRY, H. & JÉGOU, S. (2006)
Pituitary adenylate cyclase-activating polypeptide directly modulates the activity of proopiomelanocortin neurons in the rat arcuate nucleus .
Neuroscience , 143, 1, 155-163
317. MONTERO-HADJADJE, M., DELARUE, C., FOURNIER, A., VAUDRY, H. & YON, L. (2006)
Involvement of the adenylyl cyclase/protein kinase A signaling pathway in the stimulatory effect of PACAP on frog adrenocortical cells .
Annals of the New York Academy of Sciences , 1070, 431-435
316. MASMOUDI-KOUKI, O., GANDOLFO, P., LEPRINCE, J., VAUDRY, D., PELLETIER, G., FOURNIER, A., VAUDRY, H. & TONON, M. C. (2006)
PACAP stimulates biosynthesis and release of endozepines from rat astrocytes .
Annals of the New York Academy of Sciences , 1070, 411-416
315. LEBON, A., SEYER, D., COSETTE, P., COQUET, L., JOUENNE, T., CHAN, P., LEPRINCE, J., FOURNIER, A., VAUDRY, H., GONZALEZ, B. J. & VAUDRY, D. (2006)
Identification of proteins regulated by PACAP in PC12 cells by 2D gel electrophoresis coupled to mass spectrometry .
Annals of the New York Academy of Sciences , 1070, 380-387
314. GUILLEMOT, J., AÏT-ALI, D., TURQUIER, V., MONTERO-HADJADJE, M., FOURNIER, A., VAUDRY, H., ANOUAR, Y. & YON, L. (2006)
Involvement of multiple signaling pathways in PACAP-induced EM66 secretion from chromaffin cells .
Regulatory Peptides , 137, 1-2, 79-88
313. GUILLEMOT, J., AIT-ALI, D., TURQUIER, V., MONTERO-HADJADJE, M., FOURNIER, A., VAUDRY, H., ANOUAR, Y. & YON, L. (2006)
PACAP stimulates the release of the secretogranin II-derived peptide EM66 from chromaffin cells .
Annals of the New York Academy of Sciences , 1070, 309-312
312. FALLUEL-MOREL, A., VAUDRY, D., AUBERT, N., GALAS, L., BENARD, M., BASILLE, M., FONTAINE, M., FOURNIER, A., VAUDRY, H. & GONZALEZ, B. J. (2006)
PACAP and ceramides exert opposite effects on migration, neurite outgrowth, and cytoskeleton remodeling .
Annals of the New York Academy of Sciences , 1070, 265-270
311. CASTEL, H., VAUDRY, D., MEI, Y. A., LEFEBVRE, T., BASILLE, M., DESRUES, L., FOURNIER, A., VAUDRY, H., TONON, M. C. & GONZALEZ, B. J. (2006)
The delayed rectifier channel current IK plays a key role in the control of programmed cell death by PACAP and ethanol in cerebellar granule neurons .
Annals of the New York Academy of Sciences , 1070, 173-179
310. BOIVIN, S., GUILHAUDIS, L., SEGALAS-MILAZZO, I., OULYADI, H., DAVOUST, D. & FOURNIER, A. (2006)
NMR study of urotensin-II receptor structural domains .
29th European Peptide Symposium, Gdansk, Poland, September 3-8, 2006 , 120
309. BOIVIN, S., GUILHAUDIS, L., MILAZZO, I., OULYADI, H., DAVOUST, D. & FOURNIER, A. (2006)
Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide .
Biochemistry , 45, 19, 5993-6002
308. BASILLE, M., FALLUEL-MOREL, A., VAUDRY, D., AUBERT, N., FOURNIER, A., FRÉGER, P., GALLO-PAYET, N., VAUDRY, H. & GONZALEZ, B. (2006)
Ontogeny of PACAP receptors in the human cerebellum: Perspectives of therapeutic applications .
Regulatory Peptides , 137, 1-2, 27-33
307. BASILLE, M., CARTIER, D., VAUDRY, D., LIHRMANN, I., FOURNIER, A., FREGER, P., GALLO-PAYET, N., VAUDRY, H. & GONZALEZ, B. (2006)
Localization and characterization of pituitary adenylate cyclase-activating polypeptide receptors in the human cerebellum during development .
Journal of Comparative Neurology , 496, 4, 468-478
306. AUBERT, N., FALLUEL-MOREL, A., VAUDRY, D., XIFRO, X., RODRIGUEZ-ALVAREZ, J., FISCH, C., DE JOUFFREY, S., LEBIGOT, J. F., FOURNIER, A., VAUDRY, H. & GONZALEZ, B. J. (2006)
PACAP and C2-ceramide generate different AP-1 complexes through a MAP-kinase-dependent pathway: involvement of c-Fos in PACAP-induced Bcl-2 expression .
Journal of Neurochemistry , 99, 4, 1237-1250
305. THUAU, R., GUILHAUDIS, L., SÉGALAS-MILAZZO, I., CHARTREL, N., OULYADI, H., BOIVIN, S., FOURNIER, A., LEPRINCE, M., DAVOUST, D. & VAUDRY, H. (2005)
Structural studies on 26RFa, a novel human RFamide-related peptide with orexigenic activity .
Peptides , 26, 5, 779-789
304. TESSIER, S., BOIVIN, S., AUBIN, J., LAMPRON, P., DETHEUX, M. & FOURNIER, A. (2005)
Transmembrane domain V of the endothelin-A receptor is a binding domain of ETA-selective TTA-386-derived photoprobes .
Biochemistry , 44, 21, 7844-7854
303. REDROBE, J. P., DUMONT, Y., FOURNIER, A., BAKER, G. B. & QUIRION, R. (2005)
Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test .
Peptides , 26, 8, 1394-1400
302. MIGNEAULT, A., SAUVAGEAU, S., VILLENEUVE, L., THORIN, E., FOURNIER, A., LEBLANC, N. & DUPUIS, J. (2005)
Chronically elevated endothelin levels reduce pulmonary vascular reactivity to nitric oxide .
American Journal of Respiratory and Critical Care Medicine , 171, 5, 506-513
301. LANGLOIS, C., LÉTOURNEAU, M., TURCOTTE, K., DETHEUX, M. & FOURNIER, A. (2005)
PTHrP fragments 1-16 and 1-23 do not bind to either the ETA or the ETB endothelin receptors .
Peptides , 26, 8, 1436-1440
300. JOSSART, C., COUPAL, M., MCNICOLL, N., FOURNIER, A., WILKES, B. C. & DE LÉAN, A. (2005)
Photolabeling study of the ligand binding domain of natriuretic peptide receptor A: Development of a model .
Biochemistry , 44, 7, 2397-2408
299. HADDAD, S., D’ELIA, M., BERNIER, J., FOURNIER, A. & CYR, D. G. (2005)
Applications of genomics in immunotoxicology .
Investigative Immunotoxicology , 363-385
298. FALLUEL-MOREL, A., VAUDRY, D., AUBERT, N., GALAS, L., BENARD, M., BASILLE, M., FONTAINE, M., FOURNIER, A., VAUDRY, H. & GONZALEZ, B. J. (2005)
Effets du PACAP et du C2-céramide sur la motilité des neurones en grain du cervelet : rien ne sert de courir, il faut partir à point .
M S-Medecine Sciences , 21, 8-9, 696-698
297. FALLUEL-MOREL, A., VAUDRY, D., AUBERT, N., GALAS, L., BENARD, M., BASILLE, M., FONTAINE, M., FOURNIER, A., VAUDRY, H. & GONZALEZ, B. J. (2005)
Pituitary adenylate cyclase-activating polypeptide prevents the effects of ceramides on migration, neurite outgrowth, and cytoskeleton remodeling .
Proceedings of the National Academy of Sciences of the United States of America , 102, 7, 2637-2642
296. DUMONT, Y., MOYSE, E., FOURNIER, A. & QUIRION, R. (2005)
Evidence for the existence of an additional class of neuropeptide Y receptor sites in rat brain .
Journal of Pharmacology and Experimental Therapeutics , 315, 1, 99-108
295. DUMONT, Y., GAUDREAU, P., MAZZUFERI, M., LANGLOIS, D., CHABOT, J. G., FOURNIER, A., SIMONATO, M. & QUIRION, R. (2005)
BODIPY®-conjugated neuropeptide Y ligands: New fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes .
British Journal of Pharmacology , 146, 8, 1069-1081
294. DESCHÊNES, J., DUPERE, U., MCNICOLL, N., L’HEUREUX, N., AUGER, F., FOURNIER, A. & DE LÉAN, A. (2005)
Development of a selective peptide antagonist for the human natriuretic peptide receptor-B .
Peptides , 26, 3, 517-524
293. DELARUE, C., JOUET, I. R., GRAS, M., GALAS, L., FOURNIER, A. & VAUDRY, H. (2005)
Activation of endothelin(A) receptors in frog adrenocortical cells stimulates both calcium mobilization from intracellular stores and calcium influx through L-type calcium channels .
Endocrinology , 146, 1, 119-129
292. BOURGAULT, S., LÉTOURNEAU, M. & FOURNIER, A. (2005)
Development and pharmacological characterization of « caged » urotensin II analogs .
Peptides , 26, 8, 1475-1480